Sonrotoclax showed a 52.4% overall response rate and 15.5% complete response rate in relapsed/refractory MCL patients previously treated with a BTK inhibitor. The FDA granted priority review for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback